中国临床药理学杂志2017，Vol.33Issue(17)：1721-1724,4.DOI:10.13699/j.cnki.1001-6821.2017.17.031
肾移植术后使用哺乳动物西罗莫司靶蛋白抑制药的研究现状
Advances in the used of mammalian target of sirolimus inhibitors as an immunosuppressive regimen after renal transplantation
杨婧 1崔向丽 2杨辉 2刘丽宏2
作者信息
- 1. 首都医科大学药学院临床药学系,北京100069
- 2. 首都医科大学附属北京朝阳医院药事部,北京100020
- 折叠
摘要
Abstract
The choice of immunosuppressive regimen after renal transplantation is particularly important for the long-term prognosis of patients.At present,the use of mammalian target of sirolimus inhibitors (mTORi) is more and more concerned.However,a lot of clinical researches are needed in the choice of drug regimen,drug dose and concentration control range.This paper aims to summarize the relevant research,in order to known aboutthe current research status of mTORi,thus providing better clinical services for patients.关键词
临床药师/肾移植/哺乳动物西罗莫司靶蛋白抑制药Key words
clinical pharmacist/renal transplantation/mammalian target of rapamycin inhibitor分类
医药卫生引用本文复制引用
杨婧,崔向丽,杨辉,刘丽宏..肾移植术后使用哺乳动物西罗莫司靶蛋白抑制药的研究现状[J].中国临床药理学杂志,2017,33(17):1721-1724,4.
